InvestorsHub Logo
Followers 839
Posts 120737
Boards Moderated 13
Alias Born 09/05/2002

Re: dewophile post# 1601

Wednesday, 08/08/2007 8:04:03 AM

Wednesday, August 08, 2007 8:04:03 AM

Post# of 3757
>[TMC125] is a twice daily drug whereas IDIX feels the pk of their product can support once daily dosing (which in HIV we know means a lot)<

Once-daily dosing is mandatory for any drug that hopes to supersede Sustiva in a 3-drug cocktail such as Atripla. Now that SoC first-line HIV therapy has moved to once-daily dosing (e.g. Atripla, Truvada + Reyataz/ritonavir, Truvada + Kaletra), it is not going to move back to BID dosing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”